genomics

VUMC to help engage more study participants in research decisions

The All of Us Engagement Core at Vanderbilt University Medical Center is helping make human research more equitable, inclusive and stronger to accelerate the prevention and treatment of illness through genomic and precision medicine.

VUMC’s new automated biobanking system can store as many as 10 million biospecimens.

Research fellowship for genetic counselors established at Vanderbilt

Vanderbilt University School of Medicine has received a grant to establish a research fellowship for genetic counselors that will prepare them to contribute more fully to the advancement of personalized medicine.

The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer and Merck

Illumina Inc., in collaboration with Nashville Biosciences LLC, a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, have announced the five founding new members of the Alliance for Genomic Discovery.

VUMC’s new automated biobanking system can store as many as 10 million biospecimens.

Nashville Biosciences and Illumina announce sequencing agreement with Amgen

Nashville Biosciences LLC, a wholly owned subsidiary of Vanderbilt University Medical Center, and Illumina Inc., a global leader in DNA sequencing and array-based technologies, today announced an agreement with Amgen, a global biopharmaceutical company, to whole-genome sequence approximately 35,000 DNA samples.

Researchers develop framework for multiancestry genomic studies

Vanderbilt researchers have developed a framework for the analysis of multiancestry, large-scale genomic studies across multiple biobanks.

Vanderbilt biostatisticians launch Cancer-Immu data portal for predicting response to immune checkpoint blockade immunotherapy

A new data portal called Cancer-Immu established by a team of Vanderbilt University Medical Center biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors.

1 2 3